Format

Send to

Choose Destination
Diabetes Ther. 2015 Sep;6(3):239-56. doi: 10.1007/s13300-015-0127-x. Epub 2015 Aug 14.

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.

Author information

1
University of Milan, Milan, Italy. annachiara.uccellatore@multimedica.it.
2
Diabetes Endocrine and Metabolic Diseases Unit, IRCCS MultiMedica, 20099, Sesto San Giovanni, MI, Italy.
3
Diabetes Agency, Careggi Hospital, Florence, Italy.
4
Insititut d'Investigacions Biomèdiques August Pi Sunyer, Hospital Clinic, Barcelona, Spain.

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.

KEYWORDS:

GLP-1 RAs; Glucagon-like peptide-1 receptor agonists; Incretin; Type 2 diabetes mellitus

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center